Transcript-Targeted Therapy Based on RNA Interference and Antisense Oligonucleotides: Current Applications and Novel Molecular Targets
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Transcript-Targeted Therapy Based on RNA Interference and Antisense Oligonucleotides: Current Applications and Novel Molecular Targets
Authors
Keywords
-
Journal
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Volume 23, Issue 16, Pages 8875
Publisher
MDPI AG
Online
2022-08-10
DOI
10.3390/ijms23168875
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- siRNA drug Leqvio (inclisiran) to lower cholesterol
- (2022) Julia M. Migliorati et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- Combinational silencing of components involved in JAK/STAT signaling pathway
- (2022) Emira Bousoik et al. EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES
- A first-in-human phase 0 clinical study of RNA interference–based spherical nucleic acids in patients with recurrent glioblastoma
- (2021) Priya Kumthekar et al. Science Translational Medicine
- Specific targeting of the KRAS mutational landscape in myeloma as a tool to unveil the elicited anti-tumor activity.
- (2021) Antonio Sacco et al. BLOOD
- Teprasiran, A Small Interfering RNA, for the Prevention of Acute Kidney Injury in High-Risk Patients Undergoing Cardiac Surgery: A Randomized Clinical Study
- (2021) Matthias Thielmann et al. CIRCULATION
- Conditional Antisense Oligonucleotides Triggered by miRNA
- (2021) Jiahui Zhang et al. ACS Chemical Biology
- STAT3 as a mediator of oncogenic cellular metabolism: Pathogenic and therapeutic implications
- (2021) Isidora Tošić et al. NEOPLASIA
- Phase 1–2 Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS
- (2020) Timothy Miller et al. NEW ENGLAND JOURNAL OF MEDICINE
- Clusterin: Always protecting. Synthesis, function and potential issues
- (2020) Carmen Rodríguez-Rivera et al. BIOMEDICINE & PHARMACOTHERAPY
- The current state and future directions of RNAi-based therapeutics
- (2019) Ryan L. Setten et al. NATURE REVIEWS DRUG DISCOVERY
- Experimental therapies targeting apolipoprotein C-III for the treatment of hyperlipidemia – spotlight on volanesorsen
- (2019) Dimitrios Milonas et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Differential uptake, kinetics and mechanisms of intracellular trafficking of next-generation antisense oligonucleotides across human cancer cell lines
- (2019) Emily Linnane et al. NUCLEIC ACIDS RESEARCH
- Chromosomal Density of Cancer Up-Regulated Genes, Aberrant Enhancer Activity and Cancer Fitness Genes Are Associated with Transcriptional Cis-Effects of Broad Copy Number Gains in Colorectal Cancer
- (2019) Daniele Filippo Condorelli et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Targeting Heat Shock Protein 27 in Cancer: A Druggable Target for Cancer Treatment?
- (2019) Choi et al. Cancers
- Patient-Customized Oligonucleotide Therapy for a Rare Genetic Disease
- (2019) Jinkuk Kim et al. NEW ENGLAND JOURNAL OF MEDICINE
- Apatorsen plus docetaxel versus docetaxel alone in platinum-resistant metastatic urothelial carcinoma (Borealis-2)
- (2018) Jonathan E. Rosenberg et al. BRITISH JOURNAL OF CANCER
- A phase I pharmacokinetic and pharmacodynamic study of GTI-2040 in combination with gemcitabine in patients with solid tumors
- (2018) Laeeq Malik et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Diagnosis and management of spinal muscular atrophy: Part 2: Pulmonary and acute care; medications, supplements and immunizations; other organ systems; and ethics
- (2018) Richard S. Finkel et al. NEUROMUSCULAR DISORDERS
- Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis
- (2018) David Adams et al. NEW ENGLAND JOURNAL OF MEDICINE
- Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis
- (2018) Merrill D. Benson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Oligonucleotide Drugs for Transthyretin Amyloidosis
- (2018) Joel N. Buxbaum NEW ENGLAND JOURNAL OF MEDICINE
- Application of 2′-O-(2-N-Methylcarbamoylethyl) Nucleotides in RNase H-Dependent Antisense Oligonucleotides
- (2018) Yoshiaki Masaki et al. Nucleic Acid Therapeutics
- Positive Caricature Transcriptomic Effects Associated with Broad Genomic Aberrations in Colorectal Cancer
- (2018) Daniele F. Condorelli et al. Scientific Reports
- Phase 1 study of EGFR-antisense DNA, cetuximab, and radiotherapy in head and neck cancer with preclinical correlatives
- (2018) Julie E. Bauman et al. CANCER
- STAT3 Inhibition Combined with CpG Immunostimulation Activates Antitumor Immunity to Eradicate Genetically Distinct Castration-Resistant Prostate Cancers
- (2018) Dayson Moreira et al. CLINICAL CANCER RESEARCH
- P53 in kidney injury and repair: Mechanism and therapeutic potentials
- (2018) Chengyuan Tang et al. PHARMACOLOGY & THERAPEUTICS
- Role of BRCA Mutations in Cancer Treatment with Poly(ADP-ribose) Polymerase (PARP) Inhibitors
- (2018) Isabella Faraoni et al. Cancers
- Custirsen in combination with docetaxel and prednisone for patients with metastatic castration-resistant prostate cancer (SYNERGY trial): a phase 3, multicentre, open-label, randomised trial
- (2017) Kim N Chi et al. LANCET ONCOLOGY
- Custirsen (OGX-011) combined with cabazitaxel and prednisone versus cabazitaxel and prednisone alone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (AFFINITY): a randomised, open-label, international, phase 3 trial
- (2017) Tomasz M Beer et al. LANCET ONCOLOGY
- Preclinical Mammalian Safety Studies of EPHARNA (DOPC Nanoliposomal EphA2-Targeted siRNA)
- (2017) Michael J. Wagner et al. MOLECULAR CANCER THERAPEUTICS
- FDA-Approved Oligonucleotide Therapies in 2017
- (2017) Cy A. Stein et al. MOLECULAR THERAPY
- Control of phosphorothioate stereochemistry substantially increases the efficacy of antisense oligonucleotides
- (2017) Naoki Iwamoto et al. NATURE BIOTECHNOLOGY
- Cellular uptake and trafficking of antisense oligonucleotides
- (2017) Stanley T Crooke et al. NATURE BIOTECHNOLOGY
- A Randomized, Double‐Blinded, Phase II Trial of Gemcitabine and Nab‐Paclitaxel Plus Apatorsen or Placebo in Patients with Metastatic Pancreatic Cancer: The RAINIER Trial
- (2017) Andrew H. Ko et al. ONCOLOGIST
- Adult-onset spinal muscular atrophy: An update
- (2017) R. Juntas Morales et al. REVUE NEUROLOGIQUE
- Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS
- (2017) Sarah J. Ross et al. Science Translational Medicine
- RNA splicing process analysis for identifying antisense oligonucleotide inhibitors with padlock probe-based isothermal amplification
- (2017) Xiaojun Ren et al. Chemical Science
- Silencing of Foxp3 enhances the antitumor efficacy of GM-CSF genetically modified tumor cell vaccine against B16 melanoma
- (2017) Antonio Miguel et al. OncoTargets and Therapy
- Chromosomal instability analysis and regional tumor heterogeneity in colon cancer
- (2017) Vincenza Barresi et al. Cancer Genetics
- Eteplirsen in the treatment of Duchenne muscular dystrophy
- (2017) Kenji Rowel Lim et al. Drug Design Development and Therapy
- Inhibition of STAT3 with the Generation 2.5 Antisense Oligonucleotide, AZD9150, Decreases Neuroblastoma Tumorigenicity and Increases Chemosensitivity
- (2016) Seiichi Odate et al. CLINICAL CANCER RESEARCH
- The biological effects and clinical implications of BRCA mutations: where do we go from here?
- (2016) Dominique Stoppa-Lyonnet EUROPEAN JOURNAL OF HUMAN GENETICS
- Modulation of tumor eIF4E by antisense inhibition: A phase I/II translational clinical trial of ISIS 183750-an antisense oligonucleotide against eIF4E-in combination with irinotecan in solid tumors and irinotecan-refractory colorectal cancer
- (2016) A.G. Duffy et al. INTERNATIONAL JOURNAL OF CANCER
- Knockdown of miR-25 increases the sensitivity of liver cancer stem cells to TRAIL-induced apoptosis via PTEN/PI3K/Akt/Bad signaling pathway
- (2016) Xiaoning Feng et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- Association of Human Papillomavirus and p16 Status With Outcomes in the IMCL-9815 Phase III Registration Trial for Patients With Locoregionally Advanced Oropharyngeal Squamous Cell Carcinoma of the Head and Neck Treated With Radiotherapy With or Without Cetuximab
- (2016) David I. Rosenthal et al. JOURNAL OF CLINICAL ONCOLOGY
- MiR-137 and miR-34a directly target Snail and inhibit EMT, invasion and sphere-forming ability of ovarian cancer cells
- (2016) Peixin Dong et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Synthesis of Phosphorodiamidate Morpholino Oligonucleotides and Their Chimeras Using Phosphoramidite Chemistry
- (2016) Sibasish Paul et al. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
- Reciprocal positive selection for weakness - preventing olaparib resistance by inhibiting BRCA2
- (2016) Mateusz Rytelewski et al. Oncotarget
- Validation of a network-based strategy for the optimization of combinatorial target selection in breast cancer therapy: siRNA knockdown of network targets in MDA-MB-231 cells as an in vitro model for inhibition of tumor development
- (2016) Tatiana M. Tilli et al. Oncotarget
- Generation 2.5 Antisense Oligonucleotides Targeting the Androgen Receptor and Its Splice Variants Suppress Enzalutamide-Resistant Prostate Cancer Cell Growth
- (2015) Y. Yamamoto et al. CLINICAL CANCER RESEARCH
- FDA Approval Summary: Olaparib Monotherapy in Patients with Deleterious Germline BRCA-Mutated Advanced Ovarian Cancer Treated with Three or More Lines of Chemotherapy
- (2015) G. Kim et al. CLINICAL CANCER RESEARCH
- Transthyretin (ATTR) amyloidosis: clinical spectrum, molecular pathogenesis and disease-modifying treatments
- (2015) Yoshiki Sekijima JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
- Antisense Inhibition of Apolipoprotein C-III in Patients with Hypertriglyceridemia
- (2015) Daniel Gaudet et al. NEW ENGLAND JOURNAL OF MEDICINE
- AZD9150, a next-generation antisense oligonucleotide inhibitor of STAT3 with early evidence of clinical activity in lymphoma and lung cancer
- (2015) David Hong et al. Science Translational Medicine
- RNAi therapy targeting KRAS in combination with chemotherapy for locally advanced pancreatic cancer patients
- (2015) Talia Golan et al. Oncotarget
- Preclinical Evaluation of the Toxicological Effects of a Novel Constrained Ethyl Modified Antisense Compound Targeting Signal Transducer and Activator of Transcription 3 in Mice and Cynomolgus Monkeys
- (2015) Sebastien A. Burel et al. Nucleic Acid Therapeutics
- Androgen receptor: structure, role in prostate cancer and drug discovery
- (2014) MH Eileen Tan et al. ACTA PHARMACOLOGICA SINICA
- Central role of Snail1 in the regulation of EMT and resistance in cancer: a target for therapeutic intervention
- (2014) Samantha Kaufhold et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Delivery of Antisense Peptide Nucleic Acids to Cells by Conjugation with Small Arginine-Rich Cell-Penetrating Peptide (R/W)9
- (2014) Céline Cordier et al. PLoS One
- Antisense Oligonucleotide Therapies
- (2014) Kendall S. Frazier TOXICOLOGIC PATHOLOGY
- Exon-Skipping Antisense Oligonucleotides to Correct Missplicing in Neurogenetic Diseases
- (2014) Kavitha Siva et al. Nucleic Acid Therapeutics
- Therapeutic antisense oligonucleotides against cancer: hurdling to the clinic
- (2014) Pedro M. D. Moreno et al. Frontiers in Chemistry
- KRAS mutant allele-specific imbalance is associated with worse prognosis in pancreatic cancer and progression to undifferentiated carcinoma of the pancreas
- (2013) Alyssa M Krasinskas et al. MODERN PATHOLOGY
- Tumor Mutation Burden Forecasts Outcome in Ovarian Cancer with BRCA1 or BRCA2 Mutations
- (2013) Nicolai Juul Birkbak et al. PLoS One
- Mutant allele-specific imbalance modulates prognostic impact of KRAS mutations in colorectal adenocarcinoma and is associated with worse overall survival
- (2012) D. J. Hartman et al. INTERNATIONAL JOURNAL OF CANCER
- Peptide-mediated Cell and In Vivo Delivery of Antisense Oligonucleotides and siRNA
- (2012) Peter Järver et al. Molecular Therapy-Nucleic Acids
- Delayed Graft Function in the Kidney Transplant
- (2011) A. Siedlecki et al. AMERICAN JOURNAL OF TRANSPLANTATION
- Regulatory T cells and Foxp3
- (2011) Alexander Y. Rudensky IMMUNOLOGICAL REVIEWS
- KRAS mutant allele-specific imbalance in lung adenocarcinoma
- (2011) Simion I Chiosea et al. MODERN PATHOLOGY
- The underlying mechanism for the PARP and BRCA synthetic lethality: Clearing up the misunderstandings
- (2011) Thomas Helleday Molecular Oncology
- Ocular neuroprotection by siRNA targeting caspase-2
- (2011) Z Ahmed et al. Cell Death & Disease
- Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial
- (2010) Frederick J Raal et al. LANCET
- Understanding and Targeting the Eukaryotic Translation Initiation Factor eIF4E in Head and Neck Cancer
- (2009) Biljana Culjkovic et al. Journal of Oncology
- Clusterin knockdown using the antisense oligonucleotide OGX-011 re-sensitizes docetaxel-refractory prostate cancer PC-3 cells to chemotherapy
- (2008) Richard D. Sowery et al. BJU INTERNATIONAL
- The role of hypoxia-inducible factors in tumorigenesis
- (2008) E B Rankin et al. CELL DEATH AND DIFFERENTIATION
- Custirsen (OGX-011): a second-generation antisense inhibitor of clusterin for the treatment of cancer
- (2008) Kim N Chi et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- A Synthetic Lethal Therapeutic Approach: Poly(ADP) Ribose Polymerase Inhibitors for the Treatment of Cancers Deficient in DNA Double-Strand Break Repair
- (2008) Alan Ashworth JOURNAL OF CLINICAL ONCOLOGY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now